Friday, July 1, 2016
Opko Health, a multinational biopharmaceutical and diagnostics company, has signed a merger agreement to acquire Bio-Reference Laboratories, a Warwick, R.I.-based full service diagnostic laboratory. Bio-Reference Laboratories common stock holders will receive 2.75 shares of Opko common stock for each share of Bio-Reference common stock. Based on a closing price of $19.12 per share of Opko common stock on June 3, the transaction is valued at approximately $1.47 billion, or $52.58 per share of Bio-Reference common stock.
OPKO Health, a multinational biopharmaceutical and diagnostics company, has acquired EirGen Pharma, a specialty pharmaceutical company focused on the development and commercial supply of high-potency, high-barrier-to-entry pharmaceutical products for sale in the U.S., Canada, Japan, Australia, most European countries and more than 40 others around the world.
Albany Molecular Research (AMRI), a global contract research and manufacturing organization, has hired Jimmy Wang, Ph.D., to fill the newly created position of chief information officer, effective immediately. He replaces Carl Neumann, senior director, information technology, who retires this month.
OPKO Health, a multinational biopharmaceutical and diagnostics company, and Pfizer have entered into a worldwide agreement for the development and commercialization of OPKO’s long-acting hGH-CTP for the treatment of growth hormone deficiency (GHD) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by two years of age.
OPKO Health, a multinational pharmaceutical and diagnostics company, has selected Malvern, Pa.-based DSG’s eCaseLink integrated suite for self-building of harmonized electronic data capture (EDC), IWRS, drug safety event capture and case reporting and CTMS systems. DSG’s team will support the OPKO team and their site users.
OPKO Health, a multinational biopharmaceutical and diagnostics company, has acquired Prolor Biotech, a clinical-stage biopharmaceutical company. Stockholders of Prolor will receive 0.9951 shares of OPKO common stock for each share of Prolor common stock. The stockholders of both companies approved all proposals presented at their respective stockholder meetings.
OPKO Health, a multinational biopharmaceutical and diagnostics company, has signed a definitive merger agreement to acquire Prolor Biotech, a biopharmaceutical company focused on developing and commercializing longer-acting proprietary versions of already approved therapeutic proteins, in an all-stock transaction.